EMCDDA news
Report on the risk assessment of 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) in the framework of the Council Decision on new psychoactive substances
EMCDDA at 3rd Inter-sessional meeting of the UN Commission on Narcotic Drugs
Today, EMCDDA Director Alexis Goosdeel is addressing the 3rd Inter-sessional meeting of the United Nations Commission on Narcotic Drugs (CND) in Vienna. The four-day meeting will focus on: demand reduction; access to controlled substances for medical and scientific purposes; cross-cutting issues, such as human rights; and preparations for the next CND session (March 2019). 25.09.2018
Čtěte více
Viral hepatitis policies in Europe (topic overview)
European evidence-based guidance on prevention and control of HCV in prison settings (poster)
EMCDDA at 7th International Symposium on Hepatitis Care in Substance Users
This week, the EMCDDA is participating in the 7th International Symposium on Hepatitis Care in Substance Users, organised by the International Network for Hepatitis in Substance Users (INHSU). The event, running from 19–21 September in Cascais, is exploring the latest advances in hepatitis C epidemiology, management and treatment of viral hepatitis among people who use drugs, with a specific focus on hepatitis C. 19.09.2018
Čtěte více
EMCDDA Director meets President of the European Forum for Urban Security
Director Alexis Goosdeel was in Belgium today where he met with Willy Demeyer, Mayor of Liège and currently President of the European Forum for Urban Security (EFUS). The purpose of the meeting was to explore possible cooperation between the EMCDDA and the forum. 14.09.2018
Čtěte více
